Abstract
Background: Thyroid cancer is the most common type of endocrine malignancy. More than 90% of cases are diagnosed as differentiated thyroid carcinoma, with the papillary type being the most prevalent. Papillary thyroid carcinoma (PTC) with a maximum diameter ≤1 cm is associated with a distinct prognosis and treatment approach compared to larger PTCs. Objectives: To investigate Histopathological Characteristics and Treatment Approaches for Thyroid Carcinomas ≤1 cm at the Hospital of Hue University of Medicine and Pharmacy. Materials and Methods: A cross-sectional and retrospective descriptive study on 122 patients definitively diagnosed with thyroid carcinoma, with the size of the tumor ≤1 cm, at the University of Medicine and Pharmacy Hospital, Hue University, between February 2024 and December 2024. Results: 72.1% of patients were under 55 years of age, with the female-to-male ratio of 7:1. PTC accounted for 95.9%, with 66.5% being the classic subtype; 74.6% had solitary tumors; 15.6% with thyroid capsule invasion; 77.9% without lymph node involvement; 99.2% without vascular invasion; 95.1% were diagnosed at stage I. Total thyroidectomy was performed in 66.4% of cases, accompanied by 59% lymph node dissection, while 33.6% underwent lobectomy. 74.6% and 67.2% of cases were indicated for I-131 and Thyrosine, respectively. 12.3% had postoperative complications, and hypocalcemia was the most common complication (10.7%). Conclusion: Papillary thyroid carcinoma accounted for most cases (95.9%). Surgery is the primary treatment option (100%). The postoperative complication rate was relatively low (12.3%), with a statistically significant association between the type of surgical procedure and risk of postoperative hypocalcemia observed.
| Published | 2025-12-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 15 No. 6 (2025) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2025.6.591 | |
| Keywords | PAPILLARY THYROID CARCINOMA, maximum diameter ≤1 cm, Histopathological Characteristics and Treatment Approaches |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Hue Journal of Medicine and Pharmacy
Krajewska J, Kukulska A, Oczko-Wojciechowska M, Kotecka-Blicharz A, Drosik-Rutowicz K, Haras-Gil M, et al. Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival. Front Endocrinol (Lausanne). 2020;11(October):1–15.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2022: An overview. Int J Cancer. 2024;149(4):778–89.
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid Carcinoma, Version 2.2022 NCCN clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw. 2022;20(8):925–51.
Vũ Thị Hải, Trần Hải, Nguyễn Tuấn Đạt NQB. Đặc điểm lâm sàng, cận lâm sàng của bệnh nhân ung thư biểu mô tuyến giáp có kích thước u ≤ 1 cm. Tạp chí Nội tiết và Đái tháo đường. 2021;(49):76–82.
Sugitani I, Kiyota N, Ito Y, Onoda N, Hiromasa T, Horiuchi K, et al. The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery. Endocr J. 2025 May;72(5):545–635.
Lee JS, Lee JS, Yun HJ, Kim SM, Chang H, Lee YS, et al. Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm. J Clin Endocrinol Metab. 2023 May;108(6):1370–5.
Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): What changed and why? Thyroid. 2017;27(6):751–6.
Soegaard Ballester JM, Finn CB, Ginzberg SP, Kelz RR, Wachtel H. Thyroid cancer pathologic upstaging: Frequency and related factors. Am J Surg. 2023;226(2):171–5.
Nguyễn Thị Quỳnh Giang, Nguyễn Văn Chủ và cs. Đặc điểm mô bệnh học của ung thư biểu mô tuyến giáp biệt hóa tại Bệnh viện Nội tiết Trung Ương năm 2023. Tạp chí Y học Việt Nam [Internet]. 2024;(3):9–12.
Morand GB, Tessler I, Krasner J, Pusztaszeri MP, Yamin T, Gecel NA, et al. Investigation of genetic sex-specific molecular profile in well-differentiated thyroid cancer: Is there a difference between females and males? Clin Otolaryngol. 2023;48(5):748–55.
Linhares SM, Handelsman R, Picado O, Farrá JC, Lew JI. Fine needle aspiration and the Bethesda system: Correlation with histopathology in 1,228 surgical patients. Surgery. 2021 Nov;170(5):1364–8.
Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, et al. Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. Thyroid. 2015;25(5):503–8.
Almukhtar ZK. Histopathological Types of Papillary Thyroid Carcinoma: Clinicopathologic Study. Open Access Maced J Med Sci. 2022;10(January 2021):79–83.
Maksimovic S, Jakovljevic B, Gojkovic Z. Lymph Node Metastases Papillary Thyroid Carcinoma and their Importance in Recurrence of Disease. Med Arch (Sarajevo, Bosnia Herzegovina). 2018 Apr;72(2):108–11.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov;19(11):1167–214.
Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol Off J Eur Soc Med Oncol. 2019 Dec;30(12):1856–83.
Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer. Endocr J. 2020;advpub.
Nguyễn Xuân Hậu. Kết quả phẫu thuật ung thư tuyến giáp thể biệt hóa ở nam giới. Tạp chí nghiên cứu Y học. 2021;138(2):132–9.